The interim experts' council resolution on the EMPA-REG OUTCOME trial issues

M. V. Shestakova; S. A. Boytsov; O. M. Drapkina; T. Yu Demidova; H. Drexel; M. B. Antsiferov; N. A. Petunina; N. A. Chernikova; V. Yu Kalashnikov; T. P. Bardymova; V. K. Protasov; A. Yu Babenko; L. A. Ruyatkina; V. V. Klimontov; V. V. Salukhov; V. V. Fadeev; Yu A. Karpov

Journal ArticleOPEN ACCESS

The interim experts' council resolution on the EMPA-REG OUTCOME trial issues

Shestakova M
Boytsov S
Drapkina O
et al.

Rational Pharmacotherapy in Cardiology (2016) 12(2) 186-190

DOI: 10.20996/1819-6446-2016-12-2-186-190

3Citations

8Readers

Abstract

The interdisciplinary interim experts' council on March 3, 2016 in Moscow have considered the EMPA-REG OUTCOME trial results and suggested a number of propositions and recommendations on further empagliflozin's cardiovascular effects investigation and its clinical application in patients with type 2 diabetes at high cardiovascular risk.

Author supplied keywords

Cardiovascular morbidity and mortality
EMPA-REG OUTCOME trial
Empagliflozin
Type 2 diabetes mellitus

Cite

CITATION STYLE

APA

Shestakova, M. V., Boytsov, S. A., Drapkina, O. M., Demidova, T. Y., Drexel, H., Antsiferov, M. B., … Karpov, Y. A. (2016). The interim experts’ council resolution on the EMPA-REG OUTCOME trial issues. Rational Pharmacotherapy in Cardiology, 12(2), 186–190. https://doi.org/10.20996/1819-6446-2016-12-2-186-190

The interim experts' council resolution on the EMPA-REG OUTCOME trial issues

Abstract

Author supplied keywords

Cite

Register to see more suggestions